ScieGen Pharmaceuticals

Executive Summary

ScieGen Pharmaceuticals, founded in 2011 and headquartered in Hauppauge, New York, is a US-based generic pharmaceutical company specializing in sterile injectable products. The company develops and manufactures high-quality, cost-effective alternatives to branded injectable drugs, targeting various therapeutic areas including anesthetics, anti-infectives, and cardiovascular drugs. With a focus on the growing injectable generics market, ScieGen aims to address the demand for affordable sterile medications in hospitals and clinics. As a privately held company, ScieGen has built a portfolio that leverages its manufacturing capabilities and regulatory expertise to navigate the complex FDA approval process for abbreviated new drug applications (ANDAs). The company's success hinges on its ability to secure timely approvals and commercialize products in a competitive landscape dominated by larger players.

Upcoming Catalysts (preview)

• Q3 2026FDA approval of key ANDA for a high-value sterile injectable70% success
• Q4 2026Expansion of manufacturing capacity or new facility qualification60% success
• H1 2027Strategic partnership or distribution agreement for existing pipeline products50% success